OpGen Inc (NASDAQ:OPGN) stock is trading higher following two SEC filings from the precision medicine company.
The company has received an advanced payment of €750,000 related to the sale of certain Unyvero A50 systems by Curetis to a strategic partner.
The strategic partner may, in its discretion, purchase additional Unyvero A50 systems from Curetis while the parties continue to pursue a potential strategic transaction.
The company intends to use the advance payment to fund Curetis’ and Ares Genetics’ operations while negotiating with the strategic partner.
OpGen also announced a Preferred Stock Purchase Agreement. It signed an agreement with a certain investor to acquire 1,000 shares priced at $1,000 each, with gross proceeds of $1 million.
The Private Placement was conducted in connection with the negotiation of a potential strategic transaction involving the company and the Investor.
OpGen stock is gaining on heavy volume, with a session volume of 14.9 million shares traded, compared to the trailing 100-day volume of 2.24 million shares.
Price Action: OPGN shares are up 578.6% at $2.28 during the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
